| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.26▼ | 3.27▼ | 3.28▼ | 3.37▼ | 3.59▼ |
| MA10 | 3.28▼ | 3.29▼ | 3.34▼ | 3.49▼ | 4.28▼ |
| MA20 | 3.27▼ | 3.36▼ | 3.39▼ | 3.78▼ | 4.35▼ |
| MA50 | 3.29▼ | 3.41▼ | 3.46▼ | 4.39▼ | 4.44▼ |
| MA100 | 3.34▼ | 3.47▼ | 3.60▼ | 4.43▼ | 5.65▼ |
| MA200 | 3.39▼ | 3.65▼ | 4.03▼ | 4.34▼ | 7.11▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | -0.010▼ | -0.015▼ | -0.023▼ | -0.140▼ |
| RSI | 36.894▼ | 30.754▼ | 31.971▼ | 31.427▼ | 38.284▼ |
| STOCH | 33.333 | 19.055▼ | 11.767▼ | 10.427▼ | 11.111▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -98.969▼ | -99.688▼ |
| CCI | -172.131▼ | -104.046▼ | -115.057▼ | -137.778▼ | -109.929▼ |
|
Tuesday, January 27, 2026 10:59 PM
(RTTNews) - Altimmune, Inc. (ALT), a late clinical-stage biopharmaceutical company, said it entered into an agreement with a new fundamental institutional investor for the purchase and sale of 17.05 ...
|
|
Tuesday, January 06, 2026 01:29 PM
(RTTNews) - Altimmune Inc. (ALT) announced that the U.S. FDA granted Breakthrough Therapy Designation for Pemvidutide, its balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of ...
|
|
Tuesday, January 06, 2026 08:53 AM
Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide, a novel, investigational GLP-1/glucagon dual receptor agonist, for the ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/03/26 | 3.37 | 3.385 | 3.23 | 3.24 | 3,274,784 |
| 23/03/26 | 3.39 | 3.53 | 3.31 | 3.44 | 3,411,051 |
| 20/03/26 | 3.43 | 3.52 | 3.31 | 3.34 | 12,489,854 |
| 19/03/26 | 3.38 | 3.51 | 3.34 | 3.42 | 2,659,600 |
| 18/03/26 | 3.50 | 3.52 | 3.36 | 3.42 | 3,468,900 |
| 17/03/26 | 3.63 | 3.71 | 3.515 | 3.53 | 2,521,600 |
| 16/03/26 | 3.60 | 3.68 | 3.54 | 3.62 | 2,630,063 |
| 13/03/26 | 3.62 | 3.68 | 3.47 | 3.50 | 3,101,900 |
| 12/03/26 | 3.75 | 3.76 | 3.58 | 3.60 | 2,928,273 |
| 11/03/26 | 3.89 | 3.91 | 3.74 | 3.80 | 2,869,453 |
|
|
||||
|
|
||||
|
|